Three Year C-Path Longitudinal Study Identifies Gait and Balance as Primary Functional Burdens in Early Parkinson’s Disease

C-Path study follows early Parkinson's for 3 years, using wearables to show how gait and balance issues drive functional decline even when symptoms plateau.

By: AXL Media

Published: Mar 11, 2026, 6:38 AM EDT

Source: The information in this article was sourced from Critical Path Institute

The Evolution of Functional Impairment in Early PD

A multi-year prospective study has provided a comprehensive look at the trajectory of Parkinson’s disease, revealing that the functional impacts on patients often outpace the stabilization of individual symptoms. Researchers found that even when specific clinical markers appeared to reach a plateau, the overall functional impairment of participants continued to worsen over the 36-month observation period. This divergence suggests that traditional clinical assessments may fail to capture the cumulative strain of the disease. According to the study’s senior author, Dr. Jamie Adams, formally integrating these patient perspectives into the scientific record represents a fundamental shift in how medical professionals approach long-term clinical observation.

Quantifying the Real World Impact of Mobility Issues

The research identified gait, balance, and posture as the most significant and bothersome issues for individuals living with early-stage Parkinson’s. By utilizing wearable devices to monitor participants in their natural environments, the study team was able to record the increasing physical effort required for standard daily activities. These real-world measures provided a more nuanced view of disease progression than periodic in-clinic evaluations, which often capture only a snapshot of a patient's condition. The data suggests that as mobility decreases, the psychosocial burden on the individual increases, creating a compounding effect that impacts the overall quality of life.

Digital Health Technologies in Clinical Trial Design

The integration of digital health technologies is becoming a cornerstone of modern drug development, offering a more continuous and objective stream of data. The Critical Path Institute (C-Path) advocates for these tools to be placed directly in the hands of drug developers to create more efficient and patient-centered clinical trials. By combining longitudinal patient-reported assessments with digital measures of balance and movement, researchers can establish a more robust baseline for measuring the efficacy of new therapeutics. Cheryl Coon, Ph.D., of C-Path, noted that these findings align with the organization's core competencies in advancing patient-focused drug development through validated outcome assessments.